CymaBay Therapeutics Inc. (Nasdaq: CBAY) to Ring The Nasdaq Stock Market Closing Bell

What: 

CymaBay Therapeutics Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Harold Van Wart, Chief Executive Officer will ring the Closing Bell. 

Where:

Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:

Monday, May 18, 2015 – 3:45 p.m. to 4:00 p.m. ET        

CymaBay Therapeutics Inc. Media Contact:

Sujal Shah(510) [e-mail]

Nasdaq MarketSite:

Christine Barna(646) [e-mail]

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.

For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq

For news tweets, please visit our Twitter page at: http://twitter.com/nasdaq

For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/

Webcast:

A webcast of the Nasdaq Closing Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.      

About CymaBay Therapeutics Inc. (Nasdaq:CBAY):

CymaBay Therapeutics, Inc. (Nasdaq:CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Arhalofenate, the company's lead product candidate, has shown two therapeutic actions in a single drug in multiple Phase 2 gout studies. In gout patients, arhalofenate is intended to prevent painful flares in joints while at the same time promoting excretion of uric acid by the kidney, thereby addressing both the signs and symptoms of gout and the hyperuricemia that is the root cause of the disease. CymaBay's second product candidate, MBX-8025 is a potent, selective, orally active PPARδ agonist. A Phase 2 study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay has initiated a Phase 2 pilot study of MBX-8025 in patients with homozygous familial hypercholesterolemia.

For additional information about CymaBay visit www.cymabay.com.

About Nasdaq:

Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of approximately $9.5 trillion and more than 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.

-NDAQA-